LENZ Therapeutics (LENZ) EBIT Margin (2025 - 2026)
LENZ Therapeutics (LENZ) reported EBIT Margin of 2321.67% for Q1 2026, down 854.51% quarter-over-quarter from 307.7% in Q4 2025.
LENZ Therapeutics (LENZ) EBIT Margin (2025 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of EBIT Margin data on file, last reported at 2321.67% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 2321.67%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 1714.85% (changed N/A YoY), and the FY2025 annual result was 1822.76%, changed N/A from the prior year.
- EBIT Margin declined to 2321.67% in Q1 2026 per LENZ's latest filing, from 307.7% in the prior quarter.
- Over five years, EBIT Margin peaked at 307.7% in Q4 2025 and troughed at 2321.67% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | LENZ Therapeutics | 192.19 Mn | 192.19 Mn | 825,000.00 | -2,321.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,321.67% |
| Dec 31, 2025 | 307.70% |
| Sep 30, 2025 | -151.10% |
| Jun 30, 2025 | -337.14% |